Advertisement
Canada markets open in 5 hours 1 minute

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7314
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    83.17
    +0.36 (+0.43%)
     

  • Bitcoin CAD

    87,521.33
    -3,654.70 (-4.01%)
     

  • CMC Crypto 200

    1,363.30
    -19.28 (-1.40%)
     

  • GOLD FUTURES

    2,338.70
    +0.30 (+0.01%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,487.25
    -177.25 (-1.00%)
     

  • VOLATILITY

    16.16
    +0.19 (+1.19%)
     

  • FTSE

    8,088.03
    +47.65 (+0.59%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Nabriva's Shares March Higher, Can It Continue?

Zacks Equity Research
·1 min read

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics plc NBRV. The stock has moved higher by 38.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider NBRV’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as NBRV has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

ADVERTISEMENT

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Nabriva Therapeutics AG (NBRV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research